期刊
BIOCHEMICAL SOCIETY TRANSACTIONS
卷 42, 期 -, 页码 587-592出版社
PORTLAND PRESS LTD
DOI: 10.1042/BST20130229
关键词
adenosine receptor A(2A); Alzheimer's disease; caffeine; epidemiology
资金
- France Alzheimer, La Ligue Europeenne Contre la Maladie d'Alzheimer (LECMA)/Alzheimer Forschung Initiative
- Lab Ex (excellence laboratory) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease)
- Inserm
- Centre National de la Recherche Scientifique (CNRS)
- Universite Lille 2
- Region Nord/Pas-de-Calais
- Agence Nationale de la Recherche (ADORATAU)
- ERA-Net (ABeta-ID)
- Fonds Unique Interministeriel MEDIALZ
- Inserm/Region Nord pas de Calais
- Lille 2 University
- National Institutes of Health [NS065957, MH083973, NS061844]
- U.S. Department of the Army [W81XWH-12-1-0283]
- Legacy Good Samaritan Foundation
- Fritz-Thyssen Foundation
- Bial and Fundacao para a Ciencia e a Tecnologia (FCT) (Portugal)
AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population. Definitive diagnosis of AD is based on the presence of senile plaques and neurofibrillary tangles that are identified in postmortem brain specimens. A third pathological component is inflammation. AD results from multiple genetic and environmental risk factors. Among other factors, epidemiological studies report beneficial effects of caffeine, a non-selective antagonist of adenosine receptors. In the present review, we discuss the impact of caffeine and the adenosinergic system in AD pathology as well as consequences in terms of pathology and therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据